The year in cardiovascular medicine 2020: interventional cardiology
Fernándo Alfonso, Nieves Gonzalo, Fernando Rivero, Javier Escaned
Abstract
was 36% in the invasive management group and 55% in the noninvasive management group. Several new meta-analyses, including data from the COMPLETE trial, comparing complete vs. culprit-only revascularization in STEMI patients supported the value of complete revascularization to reduce rates of re-infarction, cardiovascular mortality, and repeat revascularization with no difference in all-cause mortality. Likewise, in patients with NSTEMI, an observational study suggested that multivessel revascularization reduced 3-year rates of major adverse cardiac events (MACE) (total death, MI, any revascularization) compared with culprit-vessel-only revascularization. However, in this study, 1-stage multivessel revascularization was not superior to multistage revascularization except in low-tointermediate risk patients.